Thrivent Financial For Lutherans purchased a new position in shares of Puma Biotechnology Inc (NYSE:PBYI) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 26,255 shares of the biopharmaceutical company’s stock, valued at approximately $977,000. Thrivent Financial For Lutherans owned about 0.07% of Puma Biotechnology as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in PBYI. State Street Corp boosted its stake in shares of Puma Biotechnology by 113.1% in the fourth quarter. State Street Corp now owns 1,946,098 shares of the biopharmaceutical company’s stock valued at $59,746,000 after buying an additional 1,032,915 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its position in Puma Biotechnology by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 20,142 shares of the biopharmaceutical company’s stock valued at $618,000 after buying an additional 2,247 shares in the last quarter. Guggenheim Capital LLC boosted its position in Puma Biotechnology by 11.1% in the fourth quarter. Guggenheim Capital LLC now owns 57,731 shares of the biopharmaceutical company’s stock valued at $1,772,000 after buying an additional 5,784 shares in the last quarter. Numeric Investors LLC bought a new position in Puma Biotechnology during the fourth quarter valued at about $1,142,000. Finally, Norges Bank bought a new position in Puma Biotechnology during the fourth quarter valued at about $7,693,000. 80.98% of the stock is currently owned by institutional investors.

Shares of Puma Biotechnology Inc (NYSE PBYI) traded down 3.76% during midday trading on Thursday, reaching $85.85. 1,138,724 shares of the company were exchanged. The company’s market capitalization is $3.17 billion. The stock has a 50-day moving average price of $88.12 and a 200 day moving average price of $54.02. Puma Biotechnology Inc has a 52-week low of $28.35 and a 52-week high of $98.85.

Puma Biotechnology (NYSE:PBYI) last issued its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.06) by $0.09. Equities research analysts expect that Puma Biotechnology Inc will post ($8.43) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/03/26255-shares-in-puma-biotechnology-inc-nysepbyi-acquired-by-thrivent-financial-for-lutherans-updated-updated-updated.html.

Several research analysts have issued reports on PBYI shares. J P Morgan Chase & Co reaffirmed an “overweight” rating and issued a $89.00 price target on shares of Puma Biotechnology in a report on Wednesday, May 24th. Stifel Nicolaus reiterated a “buy” rating and set a $118.00 price objective (up from $105.00) on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Zacks Investment Research cut shares of Puma Biotechnology from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Cowen and Company reiterated a “market perform” rating on shares of Puma Biotechnology in a research report on Monday, May 22nd. Finally, Citigroup Inc. restated a “buy” rating and set a $114.00 price target on shares of Puma Biotechnology in a report on Tuesday, July 18th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Puma Biotechnology presently has an average rating of “Buy” and a consensus price target of $101.75.

In other news, SVP Richard Paul Bryce sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $87.10, for a total value of $435,500.00. Following the completion of the transaction, the senior vice president now directly owns 34,237 shares in the company, valued at approximately $2,982,042.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Adage Capital Partners Gp, L.L sold 1,235,700 shares of Puma Biotechnology stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $75.38, for a total transaction of $93,147,066.00. The disclosure for this sale can be found here. Insiders sold a total of 2,010,261 shares of company stock valued at $159,425,452 over the last 90 days. Corporate insiders own 22.70% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Institutional Ownership by Quarter for Puma Biotechnology (NYSE:PBYI)

Receive News & Stock Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related stocks with our FREE daily email newsletter.